Ramoji Kosuru

Dr. Ramoji Kosuru

Versiti Blood Center of Wisconsin, Milwaukee, Wisconsin, USA
orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2016 in European Journal of Pharmacology
Verified
Journal Article
Closed access
RKRamoji Kosuru
Ramoji Kosuru
URUddipak Rai
Uddipak Rai
SPSwati Prakash
Swati Prakash
ASAbhishank Singh
Abhishank Singh
SSSanjay Singh
Sanjay Singh

20 March 2018 in Cardiovascular Drugs and Therapy
Verified
Journal Article
Closed access
PDF file
RKRamoji Kosuru
Ramoji Kosuru
VKVidya Kandula
Vidya Kandula
URUddipak Rai
Uddipak Rai
SPSwati Prakash
Swati Prakash
ZXZhengyuan Xia
Zhengyuan Xia
SSSanjay Singh
Sanjay Singh

8 March 2016 in Cardiovascular Diabetology
Verified
Journal Article
Open access
PDF file
VKVidya Kandula
Vidya Kandula
RKRamoji Kosuru
Ramoji Kosuru
HLHaobo Li
Haobo Li
DYDan Yan
Dan Yan
QZQiqi Zhu
Qiqi Zhu
MIMichael Garnet Irwin
Michael Garnet Irwin
Diabetic cardiomyopathy (DCM) is a disorder of the heart muscle in people with diabetes that can occur independent of hypertension or vascular disease. The underlying mechanism of DCM is incompletely understood. Some transcription factors have been suggested to regulate the gene program intricate in the pathogenesis of diabetes prompted cardiac injury. Forkhead box transcription factor 1 is a pleiotropic transcription factor that plays a pivotal role in a variety of physiological processes. Altered FOXO1 expression and function have been associated with cardiovascular diseases, and the important role of FOXO1 in DCM has begun to attract attention. In this review, we focus on the FOXO1 pathway and its role in various processes that have been related to DCM, such as metabolism, oxidative stress, endothelial dysfunction, inflammation and apoptosis.

Verified
Journal Article
Open access
PDF file
RKRamoji Kosuru
Ramoji Kosuru
Magdalena ChrzanowskaMagdalena Chrzanowska
Magdalena Chrzanowska
Ca2+ is a universal intracellular signal. The modulation of cytoplasmic Ca2+ concentration regulates a plethora of cellular processes, such as: synaptic plasticity, neuronal survival, chemotaxis of immune cells, platelet aggregation, vasodilation, and cardiac excitation–contraction coupling. Rap1 GTPases are ubiquitously expressed binary switches that alternate between active and inactive states and are regulated by diverse families of guanine nucleotide exchange factors (GEFs) and GTPase-activating proteins (GAPs). Active Rap1 couples extracellular stimulation with intracellular signaling through secondary messengers—cyclic adenosine monophosphate (cAMP), Ca2+, and diacylglycerol (DAG). Much evidence indicates that Rap1 signaling intersects with Ca2+ signaling pathways to control the important cellular functions of platelet activation or neuronal plasticity. Rap1 acts as an effector of Ca2+ signaling when activated by mechanisms involving Ca2+ and DAG-activated (CalDAG-) GEFs. Conversely, activated by other GEFs, such as cAMP-dependent GEF Epac, Rap1 controls cytoplasmic Ca2+ levels. It does so by regulating the activity of Ca2+ signaling proteins such as sarcoendoplasmic reticulum Ca2+-ATPase (SERCA). In this review, we focus on the physiological significance of the links between Rap1 and Ca2+ signaling and emphasize the molecular interactions that may offer new targets for the therapy of Alzheimer’s disease, hypertension, and atherosclerosis, among other diseases.

18 April 2018 in Cellular Physiology and Biochemistry
Verified
Journal Article
Open access
PDF file
RKRamoji Kosuru
Ramoji Kosuru
YCYin Cai
Yin Cai
VKVidya Kandula
Vidya Kandula
DYDan Yan
Dan Yan
CWChunyan Wang
Chunyan Wang
ZXZhengyuan Xia
Zhengyuan Xia
Background/Aims: Pterostilbene (PT) exerts antidiabetic effects by decreasing blood glucose and modulating lipid metabolism and has been shown to attenuate myocardial ischemia-reperfusion (IR) injury in non-diabetic subjects. However, whether PT can protect against myocardial IR injury in diabetes is unknown. AMPK stimulation is indispensable in offering cardioprotection against myocardial IR injury in diabetes by limiting cardiac apoptosis. Thus, we hypothesized that PT may confer protection against myocardial IR injury in diabetes via AMPK activation. Methods: Sprague-Dawley rats at eight weeks of diabetes induction (induced by an intravenous dose of 65 mg/kg streptozotocin) were administered with vehicle or PT (20 and 40 mg/kg/day, p.o.) for four weeks (starting from week 9 to 12). At the end of week 12, myocardial IR injury was induced by subjecting the diabetic rats to 30 minutes of coronary artery ligation and followed by 2 hours of reperfusion. In in vitro studies, rat primary cardiomyocytes were incubated with low glucose (LG, 5.5 mM) or high glucose (HG, 30 mM) and exposed to 45 minutes hypoxia and 2 hours reoxygenation in the presence or absence of PT (0.5 µM) or the AMPK inhibitor compound C (CC, 5 µM). Results: PT significantly reduced post-ischemic cardiac infarct size, oxidative stress, plasma lactate dehydrogenase (LDH), creatine kinase-MB levels and apoptosis in diabetic rats. In cardiomyocytes, PT decreased hypoxia/ reoxygenation-induced oxidative stress, attenuated LDH and cleaved caspase3/caspase3 ratio and increased Bcl-2/Bax ratio and AMPK phosphorylation. However, CC administration blunted the cardioprotective effects of PT both in vivo and in vitro. Conclusion: Suppressing cardiac oxidative stress and apoptosis via AMPK stimulation may represent a primary mechanism whereby pterostilbene attenuates diabetic myocardial IR injury.

11 July 2016 in RSC Advances
Verified
Journal Article
Closed access
PDF file
MVMahalingam Rajamanickam Vijayakumar
Mahalingam Rajamanickam Vijayakumar
RKRamoji Kosuru
Ramoji Kosuru
SSSanjay Kumar Singh
Sanjay Kumar Singh
CPChandra Bhushan Prasad
Chandra Bhushan Prasad
GNGopeshwar Narayan
Gopeshwar Narayan
SSSanjay Singh
Sanjay Singh
trans-Resveratrol (RSV) is a natural molecule proved for cancer preventive and therapeutic activities without any potential side effects. In recent years, RSV is also proved for its cytotoxic potential against glioma. However, practical application of RSV in glioma chemotherapy is limited because of its low systemic circulation time and short biological half-life resulting from rapid metabolism and accelerated elimination from the blood pool. Therefore, the main objective of this study was to enhance systemic circulation time and short biological half-life of RSV using poly(D,L-lactide-co-glycolide)–D-α-tocopheryl polyethylene glycol 1000 succinate blend nanoparticles (RSV-PLGA-BNPs). RSV-PLGA-BNPs were successfully formulated and optimized by a single-emulsion solvent-evaporation technique. RSV-PLGA-BNPs were evaluated by various state of the art techniques for extensive nanoparticulate characterization. Cytotoxicity against C6 cells, cellular internalization and haemocompatibility were studied for proving anticancer potential and safety of RSV-PLGA-BNPs. Pharmacokinetic and tissue distribution studies were carried out in Charles Foster rats after intravenous (i.v) administration. RSV-PLGA-BNPs showed significantly higher cytotoxicity and excellent cell internalization in C6 glioma cells. Haemocompatibility studies suggested that RSV-PLGA-BNPs are safe for i.v administration. Pharmacokinetic studies showed prolonged systemic circulation of RSV-PLGA-BNPs up to 36 h with approximately 18.11 times higher plasma half-life than RSV solution. Tissue distribution studies showed higher brain accumulation of RSV-PLGA-BNPs than RSV. Therefore, RSV-PLGA-BNPs can be applied as a potential tool for enhancing systemic circulation and plasma half-life with superior anticancer efficacy against glioma.